Novavax Starts COVID-19 Vaccine Trials On Children Aged Between 12-17 Years

Novavax said the trials would test "the efficacy (and) safety" of the vaccine, with participants receiving either the vaccine candidate or placebo in two doses, 21 days apart.

US biotech firm Novavax said Monday it had started clinical trials of its proposed Covid-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12-17. Far fewer children have been sick with Covid-19 compared to adults, and most have mild to no symptoms, but they can be infected and spread the virus. Novavax said the trials would test "the efficacy (and) safety" of the vaccine, with participants receiving either the vaccine candidate or placebo in two doses, 21 days apart. Participants will be monitored for up to two years after their injections.